FindTrial
Sign In

Speed strength training and its effects on heart and brain health in people with Parkinson's disease

Acute effect of potent strength training on cardiovascular parameters and neurotrophic and inflammatory biomarkers in patient with Parkinson's disease of mild to moderate

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-9g9b779
Enrollment
Unknown
Registered
2025-10-06
Start date
2025-07-11
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson disease

Interventions

The study will be a randomized controlled crossover clinical trial. Intervention group: 22 participants with Parkinson's disease will undergo a single powerful strength training session consisting of
G11.427.410.698.277
E02.760.169.063.500.387.875

Sponsors

Hospital Universitário Walter Cantídio da Universidade Federal do Ceará
Lead Sponsor
Hospital Universitário Walter Cantídio da Universidade Federal do Ceará
Collaborator

Eligibility

Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: Men and women; diagnosed with Parkinson's disease according to MDS-UPDRS criteria; stages I to III on the modified Hoehn & Yahr scale; no changes in medication regimen for at least 4 weeks; literate; able to perform basic activities of daily living independently with a Schwab and England scale score of at least 80%; age equal to or greater than 40 years

Exclusion criteria

Exclusion criteria: Body mass index greater than 40 or less than 20; diagnosis of specific diseases such as Crohn's disease, ulcerative colitis, multiple sclerosis; clinical and psychological conditions that may interfere with participation or study results

Design outcomes

Primary

MeasureTime frame
Evaluate BDNF, PROBDNF, NGF, PRO-NGF, IGF1, IL6, IL10, TNF, NGFR (p75NTR), TrK1 (NTRK1), TrK2 (NTRK2), and NF-kappa-B p65 (RELA) through blood analysis using the RT-qPCR method, with RNA extraction, quantification by Nanodrop, and cDNA synthesis with GoScript™ Reverse Transcriptase—

Secondary

MeasureTime frame
Assess cortisol, oxytocin, IL6, IL1ß, IL8, and IL4 levels through saliva analysis using the ELISA method;Evaluate the SDNN, RMSSD, pNN50, VLF, LF, HF, and LF/HF ratio parameters of heart rate variability(HRV) by analyzing beat-to-beat signals (iRR) that have been filtered, processed, and analyzed in the time and frequency domains—

Countries

Brazil

Contacts

Public ContactCarlos Eduardo Da Silva

Hospital Universitário Walter Cantídio da Universidade Federal do Ceará

carlosedurbano789@gmail.com+55(85)986291992

Outcome results

None listed

Source: REBEC (via WHO ICTRP)